

## Anti-IL-5 Antibody (Reslizumab)

### Introduction

Reslizumab is a humanized monoclonal antibody that is primarily used to treat severe eosinophilic asthma. It reduces the number and activity of eosinophils by targeting and neutralizing interleukin-5 (IL-5). Reslizumab is derived from expression in mammalian cells through recombinant DNA technology. Its composition includes an antibody structure of the IgG4 subtype. Reslizumab inhibits the growth, differentiation and survival of eosinophils by blocking the binding of IL-5 to its receptor, thereby alleviating asthma symptoms.

### Product parameters

Alternative Names	Cinqair, Cinqaero, Sch 55700
Target Accession	-
Target	IL-5
CAS number	241473-69-8
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

